Validation of a sensitive and robust reversed phase-HPLC method for determination of temozolomide

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Temozolomide is a physiologically pH labile, alkylating agent used in glioblastoma multiforme. An attempt has been made to develop and validate a simple, sensitive, accurate, precise and robust HPLC method for quantification of temozolomide. Ammonium formate and acetonitrile combination used as mobile phase using BDS C18 column resulted in elution of temozolomide with retention time of 5.866 min. The various parameters, precision, accuracy and robustness of the method were evaluated. The % RSD of the parameters were acceptable (< 2 or/and 1%). The LOD and LOQ were found to be 13.13 and 39.81 ng/mL, respectively. The recovery of the drug was observed to be 99.97 to 100.93%.

Original languageEnglish
Pages (from-to)967-971
Number of pages5
JournalLatin American Journal of Pharmacy
Volume35
Issue number5
Publication statusPublished - 2016

Fingerprint

temozolomide
formic acid
High Pressure Liquid Chromatography
Alkylating Agents
Glioblastoma
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science
  • Drug Discovery

Cite this

@article{3d32014ac7d6416a9211571802e84554,
title = "Validation of a sensitive and robust reversed phase-HPLC method for determination of temozolomide",
abstract = "Temozolomide is a physiologically pH labile, alkylating agent used in glioblastoma multiforme. An attempt has been made to develop and validate a simple, sensitive, accurate, precise and robust HPLC method for quantification of temozolomide. Ammonium formate and acetonitrile combination used as mobile phase using BDS C18 column resulted in elution of temozolomide with retention time of 5.866 min. The various parameters, precision, accuracy and robustness of the method were evaluated. The {\%} RSD of the parameters were acceptable (< 2 or/and 1{\%}). The LOD and LOQ were found to be 13.13 and 39.81 ng/mL, respectively. The recovery of the drug was observed to be 99.97 to 100.93{\%}.",
author = "Zenab Attari and Lalit Kumar and Rao, {C. Mallikarjuna} and Koteshwara, {K. B.}",
year = "2016",
language = "English",
volume = "35",
pages = "967--971",
journal = "Latin American Journal of Pharmacy",
issn = "0326-2383",
publisher = "Colegio de Farmaceuticos de la Provincia de Buenos Aires",
number = "5",

}

TY - JOUR

T1 - Validation of a sensitive and robust reversed phase-HPLC method for determination of temozolomide

AU - Attari, Zenab

AU - Kumar, Lalit

AU - Rao, C. Mallikarjuna

AU - Koteshwara, K. B.

PY - 2016

Y1 - 2016

N2 - Temozolomide is a physiologically pH labile, alkylating agent used in glioblastoma multiforme. An attempt has been made to develop and validate a simple, sensitive, accurate, precise and robust HPLC method for quantification of temozolomide. Ammonium formate and acetonitrile combination used as mobile phase using BDS C18 column resulted in elution of temozolomide with retention time of 5.866 min. The various parameters, precision, accuracy and robustness of the method were evaluated. The % RSD of the parameters were acceptable (< 2 or/and 1%). The LOD and LOQ were found to be 13.13 and 39.81 ng/mL, respectively. The recovery of the drug was observed to be 99.97 to 100.93%.

AB - Temozolomide is a physiologically pH labile, alkylating agent used in glioblastoma multiforme. An attempt has been made to develop and validate a simple, sensitive, accurate, precise and robust HPLC method for quantification of temozolomide. Ammonium formate and acetonitrile combination used as mobile phase using BDS C18 column resulted in elution of temozolomide with retention time of 5.866 min. The various parameters, precision, accuracy and robustness of the method were evaluated. The % RSD of the parameters were acceptable (< 2 or/and 1%). The LOD and LOQ were found to be 13.13 and 39.81 ng/mL, respectively. The recovery of the drug was observed to be 99.97 to 100.93%.

UR - http://www.scopus.com/inward/record.url?scp=84964905137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964905137&partnerID=8YFLogxK

M3 - Article

VL - 35

SP - 967

EP - 971

JO - Latin American Journal of Pharmacy

JF - Latin American Journal of Pharmacy

SN - 0326-2383

IS - 5

ER -